Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Scilex Holding Company Common Stock (SCLX)

Biological Products, (no Disgnostic Substances)

https://www.scilexholding.com

Scilex Holding Co is engaged in the development and commercialization of non-opioid pain management products. The company's lead product ZTlido.

960 SAN ANTONIO ROAD
PALO ALTO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/11/2022

Market Cap

233,985,020

Shares Outstanding

157,910,000

Weighted SO

157,905,655

Total Employees

N/A

Upcoming Earnings

08/09/2024

Beta

1.2260

Last Div

0.0000

Range

0.732-3.83

Chg

-0.0200

Avg Vol

1272150

Mkt Cap

233985020

Exch

NASDAQ

Country

US

Phone

650-516-4310

DCF Diff

N/A

DCF

0.0000

Div Yield

0.0000

P/S

4.6030

EV Multiple

-3.4992

P/FV

-0.6830

Div Yield %

0.0000

P/E

-1.2333

PEG

-0.0553

Payout

0.0000

Current Ratio

0.1974

Quick Ratio

0.1853

Cash Ratio

0.0270

DSO

272.8830

DIO

58.3795

Op Cycle

331.2625

DPO

793.8508

CCC

-462.5883

Gross Margin

0.6220

Op Margin

-1.9502

Pretax Margin

-2.3386

Net Margin

-2.3388

Eff Tax Rate

-0.0006

ROA

-1.1372

ROE

0.6426

ROCE

0.6569

NI/EBT

1.0001

EBT/EBIT

1.1992

EBIT/Rev

-1.9502

Debt Ratio

1.0054

D/E

-0.4896

LT Debt/Cap

-0.1564

Total Debt/Cap

-0.9591

Int Coverage

-45.7692

CF/Debt

0.1159

Equity Multi

-0.4869

Rec Turnover

1.3376

Pay Turnover

0.4598

Inv Turnover

6.2522

FA Turnover

15.4414

Asset Turnover

0.4862

OCF/Share

0.1013

FCF/Share

0.0963

Cash/Share

0.0573

OCF/Sales

0.2396

FCF/OCF

0.9504

CF Coverage

0.1159

ST Coverage

0.1601

CapEx Coverage

20.1516

Div&CapEx Cov

20.1516

P/BV

-0.6830

P/B

-0.6830

P/S

4.6030

P/E

-1.2333

P/FCF

20.2137

P/OCF

12.0385

P/CF

12.0385

PEG

-0.0553

P/S

4.6030

EV Multiple

-3.4992

P/FV

-0.6830

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 12, 00:30 Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination GlobeNewswire Inc. Mar 27, 00:24 Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva GlobeNewswire Inc. Aug 09, 20:30 Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination GlobeNewswire Inc. Dec 26, 11:00 Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or With GlobeNewswire Inc. Nov 28, 09:00 Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S. GlobeNewswire Inc. Nov 27, 09:00 Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024 GlobeNewswire Inc. Nov 17, 09:00 Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch GlobeNewswire Inc. Oct 27, 15:38 UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees P

Revenue Product Segmentation